{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:49:24Z","timestamp":1790272164435,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc. Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41375-019-0384-1","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T09:04:46Z","timestamp":1548752686000},"page":"1736-1746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vescio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"384_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046.","journal-title":"Nat Rev Dis Prim."},{"key":"384_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360\u201376.","journal-title":"Mayo Clin Proc"},{"key":"384_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"384_CR4","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075\u201385.","journal-title":"Lancet"},{"key":"384_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519\u201327.","journal-title":"Lancet"},{"key":"384_CR6","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1038\/leu.2015.274","volume":"29","author":"M Cavo","year":"2015","unstructured":"Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F, et al. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia. 2015;29:2429\u201331.","journal-title":"Leukemia"},{"key":"384_CR7","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31:3279\u201387.","journal-title":"J Clin Oncol"},{"key":"384_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906\u201317.","journal-title":"N Engl J Med"},{"key":"384_CR9","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119:4375\u201382.","journal-title":"Blood"},{"key":"384_CR10","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","volume":"33","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, et al. Community-based phase IIIb trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015;33:3921\u20139.","journal-title":"J Clin Oncol"},{"key":"384_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301\u201310.","journal-title":"Blood"},{"key":"384_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1586\/17474086.2015.1001360","volume":"8","author":"T Guglielmelli","year":"2015","unstructured":"Guglielmelli T, Palumbo A. Multiple myeloma: is a shift toward continuous therapy needed to move forward? Expert Rev Hematol. 2015;8:253\u20136.","journal-title":"Expert Rev Hematol."},{"key":"384_CR13","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33:3459\u201366.","journal-title":"J Clin Oncol"},{"key":"384_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.89","volume":"6","author":"B Lipe","year":"2016","unstructured":"Lipe B, Vukas R, Mikhael J. The role of maintenance therapy in multiple myeloma. Blood Cancer J. 2016;6:e485.","journal-title":"Blood Cancer J"},{"key":"384_CR15","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","volume":"119","author":"H Ludwig","year":"2012","unstructured":"Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119:3003\u201315.","journal-title":"Blood"},{"key":"384_CR16","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/blood-2012-08-448563","volume":"121","author":"A Rossi","year":"2013","unstructured":"Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, et al. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013;121:1982\u20135.","journal-title":"Blood"},{"key":"384_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","volume":"111","author":"R Niesvizky","year":"2008","unstructured":"Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, et al. BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111:1101\u20139.","journal-title":"Blood"},{"key":"384_CR18","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","volume":"121","author":"UH Mellqvist","year":"2013","unstructured":"Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121:4647\u201354.","journal-title":"Blood"},{"key":"384_CR19","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol. 2012;30:2946\u201355.","journal-title":"J Clin Oncol"},{"key":"384_CR20","doi-asserted-by":"publisher","first-page":"BSR20170304","DOI":"10.1042\/BSR20170304","volume":"37","author":"CY Sun","year":"2017","unstructured":"Sun CY, Li JY, Chu ZB, Zhang L, Chen L, Hu Y. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis. Biosci Rep. 2017;37:BSR20170304.","journal-title":"Biosci Rep"},{"key":"384_CR21","unstructured":"Millennium Pharmaceuticals Inc. NINLARO\u00ae (ixazomib) capsules, for oral use. United States Prescribing Information. 2016. \n                    https:\/\/www.ninlaro.com\/prescribing-information.pdf\n                    \n                  ; Accessed December 1, 2018."},{"key":"384_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjh.14733","volume":"178","author":"S Kumar","year":"2017","unstructured":"Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, et al. Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma. Br J Haematol. 2017;178:571\u201382.","journal-title":"Br J Haematol"},{"key":"384_CR23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","volume":"124","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma. Blood. 2014;124:1047\u201355.","journal-title":"Blood"},{"key":"384_CR24","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 2014;15:1503\u201312.","journal-title":"Lancet Oncol"},{"key":"384_CR25","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","volume":"128","author":"SK Kumar","year":"2016","unstructured":"Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016;128:2415\u201322.","journal-title":"Blood"},{"key":"384_CR26","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621\u201334.","journal-title":"N Engl J Med"},{"key":"384_CR27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","volume":"124","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients. Blood. 2014;124:1038\u201346.","journal-title":"Blood"},{"key":"384_CR28","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood. 2017;130:2610\u20138.","journal-title":"Blood"},{"key":"384_CR29","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","volume":"102","author":"MV Mateos","year":"2017","unstructured":"Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017;102:1767\u201375.","journal-title":"Haematologica"},{"key":"384_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/JBM.S102328","volume":"8","author":"PG Richardson","year":"2017","unstructured":"Richardson PG, Kumar S, Laubach JP, Paba-Prada C, Gupta N, Berg D, et al. New developments in the management of relapsed\/refractory multiple myeloma - the role of ixazomib. J Blood Med. 2017;8:107\u201321.","journal-title":"J Blood Med"},{"key":"384_CR31","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2018. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)33003-4\n                    \n                  .","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"384_CR32","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609\u201317.","journal-title":"N Engl J Med"},{"key":"384_CR33","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, San Miguel J, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"384_CR34","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115\u201323.","journal-title":"Br J Haematol"},{"key":"384_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947\u201359.","journal-title":"Blood"},{"key":"384_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.60","volume":"5","author":"SK Kumar","year":"2015","unstructured":"Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015;5:e338.","journal-title":"Blood Cancer J"},{"key":"384_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679\u201386.","journal-title":"Blood"},{"key":"384_CR38","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","volume":"119","author":"MA Dimopoulos","year":"2012","unstructured":"Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012;119:2764\u20137.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0384-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:36:45Z","timestamp":1684618605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0384-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["384"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0384-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"29 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SKK: consulting fees, paid to institution, from Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune, Genentech, Oncopeptides, and Amgen. JGB: institutional research funding from Abbvie, Amgen, Bluebird, BMS, Celgene, Genentech, Glenmark, Janssen, Novartis, Poseida, Takeda, and Teva. RN: membership of advisory council or committee, consulting fees, and grants or funds from Takeda, Celgene, BMS, Amgen, and Janssen. SL: personal fees as a consultant for Millennium Pharmaceuticals Inc., Celgene, Novartis, BMS, Onyx, and Janssen, outside the submitted work. MH: membership of advisory council or committee for Pharmacyclics and Medimmune, honoraria from Celgene and Sanofi, consulting fees from Cellerant, and grants or funds from Takeda and Otsuka. AKS: consultant for: Amgen, Celgene, BMS, Janssen, Ono, and Takeda. PH: membership of advisory council or committee, and honoraria from Millennium\/Takeda and Celgene. RV: honoraria from Takeda. JLK: grant from Millennium Pharmaceuticals, Inc. during the conduct of the study. Grants from Celgene, Merck, and Novartis, and personal fees from Millennium Pharmaceuticals, Inc., Celgene, Onyx, Spectrum, Novartis, and Janssen, outside the conduct of the study. DB and EL: employment, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. PGR: consulting fees from Takeda and Celgene. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the International Conference on Harmonization, the Guidelines for Good Clinical Practice, appropriate regulatory requirements, and with approval of Institutional Review Boards at individual enrolling institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}